Skip to main content

Table 2 Patient characteristics: PET positive vs. PET negative

From: Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy

Characteristic

PET positive

PET negative

Number

92

37

Age (years) at PSMA PET (median, range)

72 (49–86)

72 (47–80)

Gleason Score [pts]

 6

8 (8.7%)

3 (8.1%)

 7a

19 (20.7%)

8 (21.6%)

 7b

23 (25.0%)

14 (37.8%)

 8

13 (14.1%)

5 (13.5%)

 9

27 (29.3%)

7 (18.9%)

 10

2 (2.2%)

Risk group (D’Amico) [pts]

 low

3 (3.3%)

2 (5.4%)

 intermediate

14 (15.2%)

7 (18.9%)

 high

75 (81.5%)

28 (75.7%)

PSA PRE-PSMA PET [ng/ml] (median/mean, range)

1.90/8.27 (0.14–150.0)

0.30/0.50 (0.13–3.24)

PSA doubling time

  ≤ 10 months

56 (77.8%)

25 (67.6%)

  > 10 months

16 (22.2%)

12 (32.4%)

ADT at time of PET [pts]

12 (13.0%)

2 (5.4%)

Activity of 68Ga-PSMA-HBED-CC [MBq] (mean, range)

191.96 (87–293)

186.78 (94–293)

  1. (Pts patients, PSA prostate specific antigen, ADT androgen deprivation therapy, MBq Mega-Becquerel)